INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES–(BUSINESS WIRE)–$INSM—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or “the Company”) (NASDAQ: INSM) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Insmed announced on December 17, 2025, that “the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.” The Company added that it would discontinue development of brensocatib. Based on this news, shares of Insmed fell by almost 16.1% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [e-mail].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[e-mail]
www.schallfirm.com